We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ADMA Biologics Inc (ADMA) USD0.0001

Sell:$6.55 Buy:$6.79 Change: $0.18 (2.60%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$6.55
Buy:$6.79
Change: $0.18 (2.60%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$6.55
Buy:$6.79
Change: $0.18 (2.60%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Contact details

Address:
C/O Adma Biologics
Inc., 465 State Route 17
RAMSEY
07446
United States
Telephone:
+1 (201) 4785552
Website:
https://www.admabiologics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADMA
ISIN:
US0008991046
Market cap:
$1.54 billion
Shares in issue:
228.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Adam Grossman
    President, Chief Executive Officer, Co-Founder, Director
  • Jerrold Grossman
    Vice Chairman of the Board, Co-Founder
  • Brian Lenz
    Chief Financial Officer, Executive Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.